ClinicalTrials.gg
Not yet recruitingNCT07627490TENS-INFIDOLUpdated Jun 4, 2026

The Potential of Transcutaneous Electrical Nerve Stimulation to Improve Pain Experienced During Posterior Branch Blocks in Patients With Lumbar Posterior Joint Syndrome

An interventional study of Stimulation with TENS, which allows the release of endorphins and Stimulation with TENS does not allow the release of endorphins in Lower Back Pain Chronic, sponsored by University Hospital, Toulouse. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Pain by University Hospital, Toulouse — 5 open to participants now, 5 under way, none of them phase 3. Pain · University Hospital, Toulouse.

Planned enrollment
7th of 16
52 · median 29
Started
2026
with 4 others
No phase
9 of 22
4 open now
Registered
21st of 22
by date

Among the 22 studies in Pain by University Hospital, Toulouse, this one is the 7th largest by planned enrollment of the 16 interventional ones that give a count, is one of 5 that started in 2026, is one of 9 with no phase, and was the 21st registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 22 studies in Pain by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Pain by University Hospital, Toulouse, or all of them as a file.
02

Study summary

Procedural pain is inadequately managed in two-thirds of patients undergoing invasive medical procedures. Several techniques exist for managing procedural pain, but they all present implementation challenges and are not without side effects. Therefore, a new, non-pharmacological, inexpensive, and easy-to-use approach would be of significant benefit. Transcutaneous electrical nerve stimulation (TENS) for pain relief could represent this alternative. Few studies have been conducted on the benefits of TENS in managing procedural pain, for example, in shoulder arthrodistension. This project proposes to study it in the context of posterior ramus infiltration in patients eligible for this indication, in the context of chronic low back pain associated with posterior joint syndrome.

03

Conditions studied

  • Lower Back Pain Chronic

Browse trials for

Keywords

  • chronic lower back pain
  • pain
  • transcutaneous electrical neurostimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic low back pain (lasting more than 3 months)
  • Patient followed in a Chronic Pain Unit (CETD, Toulouse University Hospital)
  • Clinical and radiological diagnosis (CT scan or MRI) of posterior joint syndrome
  • Patient with an indication for infiltration therapy, feasible under standard conditions

Exclusion criteria

Exclusion Criteria:

  • Spinal surgery
  • for TENS:

    • Wearing an electronic medical device (pacemakers, defibrillators, etc.)
    • Pregnancy
    • Area of cutaneous anesthesia
    • Patient with an active malignant tumor
    • Patient with deep vein thrombosis
    • Patient with damaged or fragile skin
  • Insulin-dependent or uncontrolled diabetes
  • Uncontrolled hypertension
  • Allergy to the local anesthetics used
  • Severe psychiatric disorder
  • Lumbar injection within the previous 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Interventional group with TENS in gate control mode

    Interventional group using TENS in gate control mode to allow the release of endorphins

    Procedure: Stimulation with TENS, which allows the release of endorphins · Other: Questionnaires

  • Active comparator
    Control group using TENS with placebo stimulation

    Control group using TENS with placebo stimulation that does not release endorphins

    Procedure: Stimulation with TENS does not allow the release of endorphins · Other: Questionnaires

Interventions

  • ProcedureStimulation with TENS, which allows the release of endorphins

    Stimulation with TENS at frequencies that allow the release of endorphins before infiltration

  • ProcedureStimulation with TENS does not allow the release of endorphins

    Stimulation with TENS at levels that do not allow the release of endorphins prior to infiltration

  • OtherQuestionnaires

    Pain questionnaires will need to be completed at the inclusion, one month and 3 months

06

What researchers measure

Primary outcomes

  1. Comparison of the intensity of pain experienced during the infiltration procedure between the intervention group and the placebo group

    Pain assessment using the visual analog scale

    Time frame: 3 months after the inclusion

Secondary outcomes

  1. Evaluation of satisfaction with the infiltration procedure in both groups

    Satisfaction questionnaire to be completed regarding the infiltration procedure

    Time frame: 3 months after the inclusion

  2. Comparison of the effectiveness of posterior branch block on pain in both groups

    Pain questionnaires to be completed

    Time frame: 3 months after the inclusion

  3. Assessment of pain experienced by the patient in the 2 groups

    Questionnaire on the reduction of perceived pain

    Time frame: 3 months after the inclusion

07

Study locations

1 site
  • Service de Neurologie, Hôpital Pierre Paul Riquet, Place du Docteur Baylac
    Toulouse, 31300, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 3 months is below that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 4, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Sep 1, 2028
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07627490
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Jun 4, 2026

Study contacts

Marc LABROUSSE, MD
Contact
labrousse.m@chu-toulouse.Fr
06 21 41 75 03 ext. +33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion